Some case reports have suggested that rituximab can effectively treat nephrotic syndrome, and a recent study sought to assess the safety and effectiveness of rituximab in treating patients who have steroid- and cyclosporine-resistant pediatric nephrotic syndrome.
Idiopathic nephrotic syndrome, which is characterized by edema, hypoalbuminemia, proteinuria, and hyperlipemia, is the most prevalent chronic glomerular disease in childhood. Although the disease can often be treated successfully with steroids, approximately 10% to 20% of patients develop resistance to steroid therapy. These patients may be treated with cyclosporine, but this therapy is associated with toxicity, and patients may also have disease resistant to cyclosporine. Therefore, identifying alternative treatments is critical for this group of patients.
Some case reports have suggested that rituximab can effectively treat nephrotic syndrome, and a recent study sought to assess the safety and effectiveness of rituximab in treating patients who have steroid- and cyclosporine-resistant pediatric nephrotic syndrome. The study included patients at Tehran, Iran’s Ali Asghar Children’s Hospital who were younger than 18 years and had steroid- and cyclosporine-resistant or steroid- and cyclosporine-dependent nephrotic syndrome between 2014 and 2015.
The primary endpoint of the study was treatment response. A complete response was defined as no proteinuria, and a partial response was defined as a reduction of more than 50% in protein in the patient’s 24-hour urine sample from the beginning of treatment until 3 months after the last dose.
In total, 40 patients received rituximab at a dose of 375 mg per m2 once per week for 4 weeks and were followed for up to 2 years; 23 had steroid- and cyclosporine-resistant disease, 7 had late drug-resistant nephrotic syndrome, and 10 had steroid- and cyclosporine-dependent disease.
The researchers found the following with respect to response to treatment with rituximab:
Adverse events were noted in 4 patients: 2 had leukopenia, 1 had alopecia, and 1 had eosinophila.
The researchers concluded that rituximab was effective in treating nephrotic syndrome, and was well tolerated. “In fact,” wrote the authors, “this medication can be administered with full confidence because of its high clinical efficacy, minimized drug-related side effects, and also reduced recurrence, especially in those children with steroid- and cyclosporine- dependent nephrotic syndrome.”
Reference
Hoseni R, Sabzian K, Otukesh H, et al. Efficacy and safety of rituximab in children with steroid- and cyclosporine-resistant and steroid- and cyclosporine-dependent nephrotic syndrome. Iran J Kidney Dis. 2018;12(1):27-32. http://www.ijkd.org/index.php/ijkd/article/view/3317/982. Published January 2018. Accessed February 12, 2018.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.